<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01399723</url>
  </required_header>
  <id_info>
    <org_study_id>KEMRI_CT_2010/0014</org_study_id>
    <secondary_id>SSC 1911</secondary_id>
    <nct_id>NCT01399723</nct_id>
  </id_info>
  <brief_title>Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia</brief_title>
  <official_title>Amoxicillin Versus Benzyl Penicillin for Severe Childhood Pneumonia Amongst Inpatients: An Open Label Randomised Controlled Non-inferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KEMRI-Wellcome Trust Collaborative Research Program</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Nairobi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>KEMRI-Wellcome Trust Collaborative Research Program</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to determine whether clinical outcome following initial treatment of severe
      pneumonia with oral amoxicillin is as effective as the current standard benzyl penicillin.
      The study will also provide an estimate of the proportion of Kenyan children with severe
      pneumonia who fail treatment with a single antibiotic.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Case management for the treatment of childhood acute respiratory infections has been widely
      promoted in many developing countries for over 20 years. Despite this, pneumonia continues to
      claim over 1.5 million lives of children under five annually. The use of affordable,
      easily-administered, safe, effective treatments can potentially reduce the burden of
      childhood pneumonia. The WHO recommends the use of a single antibiotic for the treatment of
      severe pneumonia. Whereas in Asia, evidence from large randomized clinical trials has changed
      policy recommendations for treatment of severe pneumonia from parenteral penicillin to oral
      amoxicillin, there is little evidence to inform a similar move in African children where
      pneumonia is associated with poorer outcomes. In this study the investigators will
      investigate effectiveness of oral amoxicillin versus the current standard treatment, benzyl
      penicillin in severe childhood pneumonia using a randomized controlled non-inferiority design
      preceded by a pilot pre-intervention phase. The investigators will also collect observational
      data HIV-exposed / infected children with severe pneumonia. 594 children aged 2 - 59 months
      admitted with clinical signs of severe pneumonia to up to 7 hospitals in Kenya will be
      randomly assigned to receive either oral amoxicillin or injectable benzyl penicillin. They
      will then be followed up for the primary outcome of pre-defined treatment failure at 48
      hours. The results of this trial will provide valuable data on the effectiveness of oral
      amoxicillin in the treatment of severe pneumonia in a population of Kenyan children and
      determine the practicability of conducting large pragmatic trials on pneumonia in Africa
      similar to those done in Asia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Failure at 48 Hours (Two Full Days After Enrollment)</measure>
    <time_frame>48 hours</time_frame>
    <description>Development of any signs of very severe pneumonia at any time Hypoxemia defined as SpO2 &lt;85% or &lt;80% for altitude &lt; or ≥1500m respectively measured after minimum of 3 minutes on ambient air Persistent vomiting (occurring within 30 minutes of administration of amoxicillin with failure to retain drug after 3 successive attempts at administration) at any time Clinical diagnosis of new bacterial co-morbid condition requiring revision of antibiotic treatment at any time Lower chest wall indrawing Temperature ≥38◦C Respiratory rate ≥5bpm of admission rate if above age-adjusted normal upper limit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Failure at or Before Discharge / Day 5 Post Enrollment (Whichever Occurs First)</measure>
    <time_frame>Patients will be followed up from the day of hospitalisation (day 0) until the day of medical discharge (average duration of 3 days) or until day 5 of hospitalisation (whichever occurs first).</time_frame>
    <description>Treatment failure as defined in the primary outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission With Diagnosis of Severe or Very Severe Pneumonia Within 14 Days of Enrollment</measure>
    <time_frame>Day 0 to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death at or Before Five Days Following Enrollment</measure>
    <time_frame>Day 0 to Day 5</time_frame>
    <description>Death defined as: in-hospital death occurring at any time after randomisation (recruitment for HIV-exposed participants) or verbal report of death of the enrolled patient from parent/guardian communicated either directly or via telephone conversation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome (Death/Readmission) at 14 Days as Determined by Telephone or Direct Interview</measure>
    <time_frame>Day 14</time_frame>
    <description>Definition of death as described in third secondary outcome measure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">561</enrollment>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>Amoxicillin 45mg/kg 12 hourly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Benzyl Penicillin 50,000IU/kg 6 hourly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>Oral 45mg/kg 12 hourly</description>
    <arm_group_label>Amoxicillin 45mg/kg 12 hourly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benzyl penicillin</intervention_name>
    <description>Intravenous 50,000IU/kg 6 hourly</description>
    <arm_group_label>Benzyl Penicillin 50,000IU/kg 6 hourly</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical signs of WHO-defined severe pneumonia

          -  Age 2 months to 59 months

        Exclusion Criteria:

          -  Clinical signs of WHO-defined very severe pneumonia

          -  Clinical or laboratory diagnosis of meningitis

          -  Clinical diagnosis of severe malnutrition (marasmus/kwashiorkor)

          -  Clinical or laboratory diagnosis of severe anaemia requiring transfusion

          -  HIV-exposure on rapid HIV antibody test (only observational data will be collected
             from these patients)

          -  Elimination of signs of severe pneumonia in a child with wheeze after outpatient
             bronchodilator therapy

          -  Chronic condition that may underlie or contribute to a presentation with respiratory
             distress such as: known chronic renal or cardiac disease, presence of cerebral palsy
             predisposing child to aspiration/hypostatic pneumonia

          -  Established bronchiectasis or congenital abnormality of the lower respiratory tract

          -  Upper airway obstruction producing stridor

          -  Admission from outpatient clinic specifically for treatment of TB

          -  Referral from another inpatient facility following treatment with injectable
             antibiotics for more than 24 hours or because the initial regimen is considered to
             have failed

          -  Documented history of &gt;48hours treatment with oral amoxicillin

          -  Failure to obtain informed consent

          -  Penicillin allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>59 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ambrose Agweyu, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kemri- Wellcome Trust Research Programme, Nairobi, Kenya</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth Obimbo, MMed</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Paediatrics and Child Health, University of Nairobi, Nairobi, Kenya</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roma Chilengi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Infectious Disease Research, Zambia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tansy Edwards, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>London School of Hygiene and Tropical Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mike English, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kemri - Wellcome Trust Research Programme, Nairobi, Kenya</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kerugoya District Hospital</name>
      <address>
        <city>Kerugoya</city>
        <state>Central</state>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Embu Provincial General Hospital</name>
      <address>
        <city>Embu</city>
        <state>Eastern</state>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kisumu East District Hospital</name>
      <address>
        <city>Kisumu</city>
        <state>Nyanza</state>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Nyanza Provincial General Hospital</name>
      <address>
        <city>Kisumu</city>
        <state>Nyanza</state>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bungoma District Hospital</name>
      <address>
        <city>Bungoma</city>
        <state>Western</state>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mbagathi District Hospital</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2011</study_first_submitted>
  <study_first_submitted_qc>July 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2011</study_first_posted>
  <results_first_submitted>January 28, 2015</results_first_submitted>
  <results_first_submitted_qc>January 28, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 13, 2015</results_first_posted>
  <last_update_submitted>January 28, 2015</last_update_submitted>
  <last_update_submitted_qc>January 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Severe pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Penicillins</mesh_term>
    <mesh_term>Penicillin G</mesh_term>
    <mesh_term>Penicillin G Benzathine</mesh_term>
    <mesh_term>Penicillin G Procaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Amoxicillin 45mg/kg 12 Hourly</title>
          <description>Amoxicillin: Oral 45mg/kg 12 hourly</description>
        </group>
        <group group_id="P2">
          <title>Benzyl Penicillin 50,000IU/kg 6 Hourly</title>
          <description>Benzyl penicillin: Intravenous 50,000IU/kg 6 hourly</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="263"/>
                <participants group_id="P2" count="264"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="263"/>
                <participants group_id="P2" count="263"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Amoxicillin</title>
          <description>Amoxicillin 45mg/kg 12 hourly</description>
        </group>
        <group group_id="B2">
          <title>Penicillin</title>
          <description>Benzyl penicillin 50000 IU 6 hourly</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="263"/>
            <count group_id="B2" value="264"/>
            <count group_id="B3" value="527"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14" lower_limit="7" upper_limit="25"/>
                    <measurement group_id="B2" value="13" lower_limit="7" upper_limit="24"/>
                    <measurement group_id="B3" value="13" lower_limit="7" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="158"/>
                    <measurement group_id="B3" value="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Kenya</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="263"/>
                    <measurement group_id="B2" value="264"/>
                    <measurement group_id="B3" value="527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Failure at 48 Hours (Two Full Days After Enrollment)</title>
        <description>Development of any signs of very severe pneumonia at any time Hypoxemia defined as SpO2 &lt;85% or &lt;80% for altitude &lt; or ≥1500m respectively measured after minimum of 3 minutes on ambient air Persistent vomiting (occurring within 30 minutes of administration of amoxicillin with failure to retain drug after 3 successive attempts at administration) at any time Clinical diagnosis of new bacterial co-morbid condition requiring revision of antibiotic treatment at any time Lower chest wall indrawing Temperature ≥38◦C Respiratory rate ≥5bpm of admission rate if above age-adjusted normal upper limit</description>
        <time_frame>48 hours</time_frame>
        <population>Intention to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin</title>
            <description>Amoxicillin 45mg/kg 12 hourly</description>
          </group>
          <group group_id="O2">
            <title>Penicillin</title>
            <description>Benzyl penicillin 50000 IU/kg 6 hourly</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Failure at 48 Hours (Two Full Days After Enrollment)</title>
          <description>Development of any signs of very severe pneumonia at any time Hypoxemia defined as SpO2 &lt;85% or &lt;80% for altitude &lt; or ≥1500m respectively measured after minimum of 3 minutes on ambient air Persistent vomiting (occurring within 30 minutes of administration of amoxicillin with failure to retain drug after 3 successive attempts at administration) at any time Clinical diagnosis of new bacterial co-morbid condition requiring revision of antibiotic treatment at any time Lower chest wall indrawing Temperature ≥38◦C Respiratory rate ≥5bpm of admission rate if above age-adjusted normal upper limit</description>
          <population>Intention to treat analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority between amoxicillin and benzyl penicillin was defined a priori as a risk difference of treatment failure and associated upper bound of the 95% confidence interval (CI) of &lt;7%. A sample size of 576 would provide 80% power to detect noninferiority of amoxicillin against benzyl penicillin within a margin of 7% at a 1-sided level of significance of 0.025, assuming a prevalence of treatment failure of 10% at 48 hours derived from a preintervention pilot phase of the study</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>4.2</ci_upper_limit>
            <estimate_desc>Risk difference comparison is for amoxicillin versus benzyl penicillin</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Failure at or Before Discharge / Day 5 Post Enrollment (Whichever Occurs First)</title>
        <description>Treatment failure as defined in the primary outcome measure.</description>
        <time_frame>Patients will be followed up from the day of hospitalisation (day 0) until the day of medical discharge (average duration of 3 days) or until day 5 of hospitalisation (whichever occurs first).</time_frame>
        <population>Intention to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin</title>
            <description>Amoxicillin 45mg/kg 12 hourly</description>
          </group>
          <group group_id="O2">
            <title>Penicillin</title>
            <description>Benzyl Penicillin 50,000IU/kg 6 hourly</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Failure at or Before Discharge / Day 5 Post Enrollment (Whichever Occurs First)</title>
          <description>Treatment failure as defined in the primary outcome measure.</description>
          <population>Intention to treat analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The initial sample size estimate of 576 children (288 per group) would provide 80% power to detect noninferiority of amoxicillin against benzyl penicillin within a margin of 7% at a 1-sided level of significance of 0.025, assuming a prevalence of treatment failure of 10% at 48 hours derived from a preintervention pilot phase of the study</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>5.8</ci_upper_limit>
            <estimate_desc>Risk difference comparison is for amoxicillin versus benzyl penicillin</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Readmission With Diagnosis of Severe or Very Severe Pneumonia Within 14 Days of Enrollment</title>
        <time_frame>Day 0 to Day 14</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death at or Before Five Days Following Enrollment</title>
        <description>Death defined as: in-hospital death occurring at any time after randomisation (recruitment for HIV-exposed participants) or verbal report of death of the enrolled patient from parent/guardian communicated either directly or via telephone conversation.</description>
        <time_frame>Day 0 to Day 5</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Outcome (Death/Readmission) at 14 Days as Determined by Telephone or Direct Interview</title>
        <description>Definition of death as described in third secondary outcome measure.</description>
        <time_frame>Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin</title>
            <description>Amoxicillin 45mg/kg 12 hourly</description>
          </group>
          <group group_id="O2">
            <title>Penicillin</title>
            <description>Benzyl Penicillin 50,000IU/kg 6 hourly</description>
          </group>
        </group_list>
        <measure>
          <title>Outcome (Death/Readmission) at 14 Days as Determined by Telephone or Direct Interview</title>
          <description>Definition of death as described in third secondary outcome measure.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The initial sample size estimate of 576 children (288 per group) would provide 80% power to detect noninferiority of amoxicillin against benzyl penicillin within a margin of 7% at a 1-sided level of significance of 0.025, assuming a prevalence of treatment failure of 10% at 48 hours derived from a preintervention pilot phase of the study</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-3.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.0</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
            <estimate_desc>Risk difference comparison is for amoxicillin versus benzyl penicillin</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Amoxicillin</title>
          <description>Amoxicillin 45mg/kg 12 hourly</description>
        </group>
        <group group_id="E2">
          <title>Benzyl Penicillin</title>
          <description>Benzyl Penicillin 50,000IU/kg 6 hourly</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypovolemic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <description>Acute on chronic kidney disease</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ambrose Agweyu</name_or_title>
      <organization>KEMRI-Wellcome Trust Research Prorgamme</organization>
      <phone>254202715160</phone>
      <email>aagweyu@kemri-wellcome.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

